Two papers published in Science provide the first clinical evidence that fecal microbial transplants (FMTs) can boost the anti-cancer efficacy of immune checkpoint inhibitors. At least eight microbiome companies have launched first-in-human trials pairing their microbiome agents with approved immunotherapies (Table 1) to satisfy the growing need to increase the proportion of patients responding to checkpoint inhibitors.
Subscribe to Journal
Get full journal access for 1 year
only 4,92 € per issue
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.